Halozyme Therapeutics Inc

NASDAQ: HALO
$38.77
+$0.20 (+0.5%)
Closing price April 29, 2024
Halozyme Therapeutics Inc is a biopharmaceutical company that specializes in developing and commercializing innovative enzyme-based therapies. Utilizing its patented recombinant human hyaluronidase enzyme (rHuPH20), Halozyme enhances the delivery of injectable biologics, including monoclonal antibodies and other therapeutic molecules. Its product lineup addresses a variety of medical conditions, from hydration and drug dispersion to treating chronic diseases such as HIV, multiple sclerosis, and various cancers. Founded in 1998, Halozyme is headquartered in San Diego, California, serving a global market.
Microsoft (NASDAQ:MSFT) has generated over $300 million in sales from Halo 3 titles in the first week alone, with $59.95 of that being from me.  There were more than 1.7 million copies...
We all know about the incredible hype and demand for Microsoft’s (NASDAQ:MSFT) monster release of HALO 3 from Bungie Studios.  The figure that is being thrown out is roughly $170 million...
The lines are out.  The costumes are on.  Halo 3 is on imminent release.  10 minutes for the east coast.  Halo 4, or the next version/series of Halo, is already under...
By now, everyone on earth knows of the launch of Halo 3.  Microsoft’s (NASDAQ:MSFT) Bungie Studios is launching this at Midnight tonight.  This should pretty easily surpass the $125...
In just under two short weeks the gaming event of 2007 will take place: Microsoft’s (NASDAQ:MSFT) Halo 3 hits the shelves.  Halo 3 will launch on September 25, 2007, and this will be a key date...